CNS Drugs

, Volume 24, Issue 4, pp 267–284 | Cite as

Defining and Measuring Functional

Recovery from Depression
  • Tracy L. Greer
  • Benji T. Kurian
  • Madhukar H. Trivedi
Review Article

Abstract

Depression is associated with significant functional impairment and reduced quality of life. Disruptions occur both globally as well as in specific functional areas such as work, interpersonal relationships and cognitive function. From both a clinical and research perspective, much focus has been given to the resolution of symptoms associated with depression, while relatively little attention has been given to functional improvements. Definitions of remission in depression are most frequently based on achieving a cut-off score on clinical rating scales of depressive symptoms. Research in this area has sparsely included psychosocial function or health-related quality of life as a primary outcome measure in clinical trials. However, the need to fully understand the impact of depression and its treatments on functioning is great, given the existing evidence of the profound effect that depression has on function. Even mild depressive symptoms and subsyndromal depression result in functional impairment and reduced quality of life, and untreated residual depressive symptomatology can result in an increased likelihood for relapse of the fully symptomatic disorder (i.e. major depressive disorder). Therefore, clinicians and researchers alike need to broaden the focus of treatment to encompass not only the specific symptoms of depression, but the functional consequences as well.

Many tools have been developed to assess function and quality of life, both globally as well as within specific domains. In addition, the effect of residual symptoms associated with functional impairment (i.e. insomnia, fatigue, pain [somatic] symptoms and cognition) in depression, even independently of depressive symptoms, warrants evaluation and monitoring. Recommendations for evaluating functional outcomes include: (i) adequately assessing functional impairment; (ii) identifying and/or developing treatment plans that will target symptoms associated with functional impairments; and (iii) monitoring functional impairments and associated symptoms throughout the course of treatment. The development of treatments that specifically target improvements in functional impairments is needed, and may require the use of novel treatment strategies.

Notes

Acknowledgements

The authors would like to thank Eric Nestler, Lou and Ellen McGinley, Distinguished Professor and Chairman, Department of Psychiatry, University of Texas Southwestern Medical Center as well as Carol A. Tamminga, M.D., Communities Foundation of Texas, Inc. Chair in Brain Science, and Interim Chair, Department of Psychiatry, University of Texas Southwestern Medical Center for administrative support. We would also like to thank Laura Cain and Shyma El Sayed for their assistance in preparing this manuscript.

No sources of funding were used to assist in the preparation of this review.

Tracy L. Greer has received grant support from the National Alliance for Research in Schizophrenia and Depression.

Madhukar H. Trivedi has been a consultant for Abbott Laboratories, Inc.; Akzo (Organon Pharmaceuticals Inc.); AstraZeneca; Bayer; Bristol-Myers Squibb Company; Cephalon, Inc.; Cyberonics, Inc.; Eli Lilly & Company; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Johnson & Johnson PRD; Meade Johnson; Neuronetics; Parke-Davis Pharmaceuticals, Inc.; Pfizer, Inc.; Pharmacia & Upjohn; Sepracor; Solvay Pharmaceuticals, Inc.; VantagePoint; and Wyeth-Ayerst Laboratories. He has served on speakers bureaus for Abdi Brahim; Akzo (Organon Pharmaceuticals Inc.); Bristol-Myers Squibb Company; Cephalon, Inc.; Cyberonics, Inc.; Forest Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Eli Lilly & Company; Pharmacia & Upjohn; Solvay Pharmaceuticals, Inc.; and Wyeth-Ayerst Laboratories. He has also received grant support from Bristol-Myers Squibb Company; Cephalon, Inc.; Corcept Therapeutics, Inc.; Cyberonics, Inc.; Eli Lilly & Company; Forest Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica; Merck; National Institute of Mental Health; National Alliance for Research in Schizophrenia and Depression; Novartis; Pfizer Inc.; Pharmacia & Upjohn; Predix Pharmaceuticals; Solvay Pharmaceuticals, Inc.; and Wyeth-Ayerst Laboratories.

Benji Kurian has received research grant support from Targacept, Inc. and National Institute of Health.

References

  1. 1.
    Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry 2001; 62Suppl. 26: 5–9PubMedGoogle Scholar
  2. 2.
    Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 2002 Jan 15; 51: 123–33PubMedCrossRefGoogle Scholar
  3. 3.
    Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998 Nov; 59: 608–19PubMedCrossRefGoogle Scholar
  4. 4.
    Gotlib IH, Lewinsohn PM, Seeley JR. Symptoms versus a diagnosis of depression: differences in psychosocial functioning. J Consult Clin Psychol 1995 Feb; 63: 90–100PubMedCrossRefGoogle Scholar
  5. 5.
    Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 1997 Aug; 45: 5–17; discussion −8PubMedCrossRefGoogle Scholar
  6. 6.
    Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000 Apr; 57: 375–80PubMedCrossRefGoogle Scholar
  7. 7.
    Judd LL, Paulus MP, Wells KB, et al. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996 Nov; 153: 1411–7PubMedGoogle Scholar
  8. 8.
    Judd LL, Rapaport MH, Paulus MP, et al. Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry 1994 Apr; 55 Suppl.: 18–28PubMedGoogle Scholar
  9. 9.
    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006 Nov; 3: 2011–30CrossRefGoogle Scholar
  10. 10.
    Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997 May 17; 349: 1436–42PubMedCrossRefGoogle Scholar
  11. 11.
    Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989 Aug 18; 262: 914–9PubMedCrossRefGoogle Scholar
  12. 12.
    Herrman H, Patrick DL, Diehr P, et al. Longitudinal investigation of depression outcomes in primary care in six countries: the LIDO study: functional status, health service use and treatment of people with depressive symptoms. Psychol Med 2002 Jul; 32: 889–902PubMedCrossRefGoogle Scholar
  13. 13.
    Coryell W, Scheftner W, Keller M, et al. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993 May; 150: 720–7PubMedGoogle Scholar
  14. 14.
    Katz MM, Secunda SK, Hirschfeld RM, et al. NIMH clinical research branch collaborative program on the psychobiology of depression. Arch Gen Psychiatry 1979 Jul; 36: 765–71PubMedCrossRefGoogle Scholar
  15. 15.
    Judd LL, Schettler PJ, Solomon DA, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 2008 May; 108: 49–58PubMedCrossRefGoogle Scholar
  16. 16.
    Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006 Sep; 31: 1841–53PubMedCrossRefGoogle Scholar
  17. 17.
    Trivedi MH, Rush AJ, Wisniewski SR, et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry 2006 Feb; 67: 185–95PubMedCrossRefGoogle Scholar
  18. 18.
    Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995 Nov; 25: 1171–80PubMedCrossRefGoogle Scholar
  19. 19.
    Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry 2006 Sep; 163: 1561–8PubMedCrossRefGoogle Scholar
  20. 20.
    Kessler RC, Ustun TB. The World Mental Health (WMH) Survey Initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004; 13: 93–121PubMedCrossRefGoogle Scholar
  21. 21.
    Kessler RC, Barber C, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med 2003; 45: 156–74PubMedCrossRefGoogle Scholar
  22. 22.
    Kessler RC, Ames M, Hymel PA, et al. Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med 2004; 46: S23–37PubMedCrossRefGoogle Scholar
  23. 23.
    Kessler RC, Heeringa S, Lakoma MD, et al. Individual and societal effects of mental disorders on earnings in the United States: results from the national comorbidity survey replication. Am J Psychiatry 2008 Jun; 165: 703–11PubMedCrossRefGoogle Scholar
  24. 24.
    Buysse DJ, Angst J, Gamma A, et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008 Apr 1; 31: 473–80PubMedGoogle Scholar
  25. 25.
    Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999; 60Suppl. 17: 28–31; discussion 46-8PubMedGoogle Scholar
  26. 26.
    Buckner JD, Bernert RA, Cromer KR, et al. Social anxiety and insomnia: the mediating role of depressive symptoms. Depress Anxiety 2008; 25: 124–30PubMedCrossRefGoogle Scholar
  27. 27.
    Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 2004; 65Suppl. 16: 27–32PubMedGoogle Scholar
  28. 28.
    Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003 Jul–Aug; 65: 528–33PubMedCrossRefGoogle Scholar
  29. 29.
    Trivedi MH. The link between depression and physical symptoms. Prim Care Companion J Clin Psychiatry 2004; 6: 12–6PubMedGoogle Scholar
  30. 30.
    Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999 Oct 28; 341: 1329–35PubMedCrossRefGoogle Scholar
  31. 31.
    Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003 Jan; 60: 39–47PubMedCrossRefGoogle Scholar
  32. 32.
    Wise TN, Meyers AL, Desaiah D, et al. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. Prim Care Companion J Clin Psychiatry 2008; 10: 270–5PubMedCrossRefGoogle Scholar
  33. 33.
    Veiel HO. A preliminary profile of neuropsychological deficits associated with major depression. J Clin Exp Neuropsychol 1997 Aug; 19: 587–603PubMedCrossRefGoogle Scholar
  34. 34.
    Jaeger J, Berns S, Uzelac S, et al. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res 2006 Nov 29; 145: 39–48PubMedCrossRefGoogle Scholar
  35. 35.
    Jaeger J, Berns S, Czobor P. The multidimensional scale for independent functioning: a new instrument for measuring functional disability in psychiatric populations. Schizophren Bull 2003; 29: 153–68CrossRefGoogle Scholar
  36. 36.
    Lopez AD, Murray CC. The global burden of disease, 1990–2020. Nat Med 1998 Nov; 4: 1241–3PubMedCrossRefGoogle Scholar
  37. 37.
    Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996 Nov 1; 274: 740–3PubMedCrossRefGoogle Scholar
  38. 38.
    Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997 May 24; 349: 1498–504PubMedCrossRefGoogle Scholar
  39. 39.
    Greenberg PE, Stiglin LE, Finkelstein SN, et al. Depression: a neglected major illness. J Clin Psychiatry 1993 Nov; 54: 419–24PubMedGoogle Scholar
  40. 40.
    Rice DP, Miller LS. The economic burden of affective disorders. Adv Health Econ Health Serv Res 1993; 14: 37–53PubMedGoogle Scholar
  41. 41.
    Stoudemire A, Frank R, Hedemark N, et al. The economic burden of depression. Gen Hosp Psychiatry 1986 Nov; 8: 387–94PubMedCrossRefGoogle Scholar
  42. 42.
    Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003 Dec; 64(12): 1465–75PubMedCrossRefGoogle Scholar
  43. 43.
    Greenberg PE, Birnbaum HG. The economic burden of depression in the US: societal and patient perspectives. Expert Opin Pharmacother 2005 Mar; 6: 369–76PubMedCrossRefGoogle Scholar
  44. 44.
    Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff (Millwood) 1999 Sep–Oct; 18: 163–71CrossRefGoogle Scholar
  45. 45.
    Salkever DS, Shinogle JA, Goldman H. Return to work and claim duration for workers with long-term mental disabilities: impacts of mental health coverage, fringe benefits, and disability management. Ment Health Serv Res 2003 Sep; 5: 173–86PubMedCrossRefGoogle Scholar
  46. 46.
    US Social Security Administration. SSI annual statistical report, 2007 [online]. Available from URL: http://www.ssa.gov/policy/docs/statcomps/ssi_asr/ [Accessed 2008 Oct 31]
  47. 47.
    Salkever DS, Goldman H, Purushothaman M, et al. Disability management, employee health and fringe benefits, and long-term-disability claims for mental disorders: an empirical exploration. Milbank Q 2000; 78: 79–113, iiiPubMedCrossRefGoogle Scholar
  48. 48.
    Davey-Rothwell MA, German D, Latkin CA. Residential transience and depression: does the relationship exist for men and women? J Urban Health 2008 Sep; 85: 707–16PubMedCrossRefGoogle Scholar
  49. 49.
    Schanzer B, Dominguez B, Shrout PE, et al. Homelessness, health status, and health care use. Am J Public Health 2007 Mar; 97: 464–9PubMedCrossRefGoogle Scholar
  50. 50.
    Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1(3): 385–401CrossRefGoogle Scholar
  51. 51.
    Naismith SL, Longley WA, Scott EM, et al. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry 2007; 7: 32PubMedCrossRefGoogle Scholar
  52. 52.
    Von Korff M, Ustun TB, Ormel J, et al. Self-report disability in an international primary care study of psychological illness. J Clin Epidemiol 1996 Mar; 49(3): 297–303CrossRefGoogle Scholar
  53. 53.
    Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 30: 473–83CrossRefGoogle Scholar
  54. 54.
    Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003 May; 56: 395–407PubMedCrossRefGoogle Scholar
  55. 55.
    Ware Jr JE. Conceptualization and measurement of health-related quality of life: comments on an evolving field. Arch Phys Med Rehabil 2003 Apr; 84(4 Suppl. 2): S43–51PubMedCrossRefGoogle Scholar
  56. 56.
    Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale: the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 1997 Apr; 7Suppl. 1: S57–70; discussion S1–3PubMedCrossRefGoogle Scholar
  57. 57.
    Bech P. Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs 2005; 19: 313–24PubMedCrossRefGoogle Scholar
  58. 58.
    Wisniewski SR, Rush AJ, Bryan C, et al. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis 2007 Mar; 195: 219–25PubMedCrossRefGoogle Scholar
  59. 59.
    Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321–6PubMedGoogle Scholar
  60. 60.
    Leon AC, Solomon DA, Mueller TI, et al. The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med 1999 Jul; 29: 869–78PubMedCrossRefGoogle Scholar
  61. 61.
    Katz MM, Klerman GL. Introduction: overview of the clinical studies program of the NIMH clinical research branch collaborative study on psychobiology of depression. Am J Psychiatry 1979; 136: 49–51PubMedGoogle Scholar
  62. 62.
    Diener E, Emmons RA, Larsen RJ, et al. The Satisfaction With Life Scale. J Pers Assess 1985 Feb; 49: 71–5PubMedCrossRefGoogle Scholar
  63. 63.
    Shevlin M, Brunsden V, Miles JNV. Satisfaction With Life Scale: analysis of factorial invariance, mean structures and reliability. Personality Individ Diff 1998; 25: 911–6CrossRefGoogle Scholar
  64. 64.
    Ware JE, Snow KK, Kosinski M, et al. SF-36 Health survey manual and interpretation guide. Boston (MA): New England Medical Center, The Health Institute, 1993Google Scholar
  65. 65.
    Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992 Jun; 30: 473–83Google Scholar
  66. 66.
    Bosc M. Assessment of social functioning in depression. Compr Psychiatry 2000 Jan-Feb; 41: 63–9PubMedCrossRefGoogle Scholar
  67. 67.
    Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997; 11(4 Suppl.): S17–23PubMedGoogle Scholar
  68. 68.
    Weissman MM, Prusoff BA, Thompson WD, et al. Social adjustment by self-report in a community sample and in psychiatric outpatients. J Nerv Ment Dis 1978 May; 166: 317–26PubMedCrossRefGoogle Scholar
  69. 69.
    Mundt JC, Marks IM, Shear MK, et al. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry 2002 May; 180: 461–4PubMedCrossRefGoogle Scholar
  70. 70.
    Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993 Nov; 4: 353–65PubMedCrossRefGoogle Scholar
  71. 71.
    Buysse DJ, Reynolds 3rd CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989 May; 28: 193–213PubMedCrossRefGoogle Scholar
  72. 72.
    Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001 Jul; 2: 297–307PubMedCrossRefGoogle Scholar
  73. 73.
    Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatr Res 1986 May; 18: 65–87CrossRefGoogle Scholar
  74. 74.
    Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996 May; 26: 477–86PubMedCrossRefGoogle Scholar
  75. 75.
    Carlsson AM. Assessment of chronic pain: I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983 May; 16: 87–101Google Scholar
  76. 76.
    de C Williams AC, Davies HT, Chadury Y. Simple pain rating scales hide complex idiosyncratic meanings. Pain 2000 Apr; 85: 457–63CrossRefGoogle Scholar
  77. 77.
    DeLoach LJ, Higgins MS, Caplan AB, et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998 Jan; 86: 102–6Google Scholar
  78. 78.
    Bowie CR, Twamley EW, Anderson H, et al. Self-assessment of functional status in schizophrenia. J Psychiatr Res 2007 Dec; 41: 1012–8PubMedCrossRefGoogle Scholar
  79. 79.
    Khatri N, Romney DM, Pelletier G. Validity of self-reports about quality of life among patients with schizophrenia. Psychiatr Serv 2001 Apr; 52: 534–5PubMedCrossRefGoogle Scholar
  80. 80.
    Crane MK, Bogner HR, Brown GK, et al. The link between depressive symptoms, negative cognitive bias and memory complaints in older adults. Aging Ment Health 2007 Nov; 11: 708–15PubMedCrossRefGoogle Scholar
  81. 81.
    Popkin SJ, Gallagher D, Thompson LW, et al. Memory complaint and performance in normal and depressed older adults. Exp Aging Res 1982 Fall-Winter; 8: 141–5PubMedCrossRefGoogle Scholar
  82. 82.
    Zeintl M, Kliegel M, Rast P, et al. Prospective memory complaints can be predicted by prospective memory performance in older adults. Dement Geriatr Cogn Disord 2006; 22: 209–15PubMedCrossRefGoogle Scholar
  83. 83.
    Chandler JD, Gerndt J. Memory complaints and memory deficits in young and old psychiatric inpatients. J Geriatr Psychiatry Neurol 1988 Apr-Jun; 1: 84–8PubMedCrossRefGoogle Scholar
  84. 84.
    Squire LR, Zouzounis JA. Self-ratings of memory dysfunction: different findings in depression and amnesia. J Clin Exp Neuropsychol 1988 Dec; 10: 727–38PubMedCrossRefGoogle Scholar
  85. 85.
    Lemke MR, Puhl P, Broderick A. Motor activity and perception of sleep in depressed patients. J Psychiatr Res 1999 May–Jun; 33: 215–24PubMedCrossRefGoogle Scholar
  86. 86.
    Matousek M, Cervena K, Zavesicka L, et al. Subjective and objective evaluation of alertness and sleep quality in depressed patients. BMC Psychiatry 2004; 4: 14PubMedCrossRefGoogle Scholar
  87. 87.
    O’Boyle M, Amadeo M, Self D. Cognitive complaints in elderly depressed and pseudodemented patients. Psychol Aging 1990 Sep; 5: 467–8PubMedCrossRefGoogle Scholar
  88. 88.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, text revision. Washington, DC: American Psychiatric Press, 2000Google Scholar
  89. 89.
    Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967 Dec; 6: 278–96PubMedCrossRefGoogle Scholar
  90. 90.
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 Apr; 134: 382–9PubMedCrossRefGoogle Scholar
  91. 91.
    Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003 Sep 1; 54: 573–83PubMedCrossRefGoogle Scholar
  92. 92.
    Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004 Jan; 34: 73–82PubMedCrossRefGoogle Scholar
  93. 93.
    Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006 Jan; 163: 28–40PubMedCrossRefGoogle Scholar
  94. 94.
    Corey-Lisle PK, Nash R, Stang P, et al. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 2004 Jun 14; 164: 1197–204PubMedCrossRefGoogle Scholar
  95. 95.
    Sackeim HA. The definition and meaning of treatmentresistant depression. J Clin Psychiatry 2001; 62Suppl. 16: 10–7PubMedGoogle Scholar
  96. 96.
    Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000 Sep; 157: 1501–4PubMedCrossRefGoogle Scholar
  97. 97.
    Solomon DA, Leon AC, Coryell W, et al. Predicting recovery from episodes of major depression. J Affect Disord 2008 Apr; 107: 285–91PubMedCrossRefGoogle Scholar
  98. 98.
    Zimmerman M, Posternak MA, Chelminski I. Is it time to replace the Hamilton Depression Rating Scale as the primary outcome measure in treatment studies of depression? J Clin Psychopharmacol 2005 Apr; 25: 105–10PubMedCrossRefGoogle Scholar
  99. 99.
    Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004 Feb; 25: 119–42PubMedCrossRefGoogle Scholar
  100. 100.
    Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006 Sep; 163: 1519–30; quiz 665PubMedCrossRefGoogle Scholar
  101. 101.
    Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry 2007 Jul-Sep; 19: 153–9PubMedCrossRefGoogle Scholar
  102. 102.
    Fava M. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol 2006 May; 20: 29–34PubMedCrossRefGoogle Scholar
  103. 103.
    Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006 Nov; 67: 1754–9PubMedCrossRefGoogle Scholar
  104. 104.
    Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999 Oct; 60: 668–76PubMedCrossRefGoogle Scholar
  105. 105.
    Fava M, McCall WV, Krystal A, et al. Eszopiclone coadministered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006 Jun 1; 59: 1052–60PubMedCrossRefGoogle Scholar
  106. 106.
    Becker PM, Sattar M. Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol 2009 Sep; 11(5): 349–57PubMedCrossRefGoogle Scholar
  107. 107.
    Gross PK, Nourse R, Wasser TE. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med 2009 Feb 15; 5(1): 28–33PubMedGoogle Scholar
  108. 108.
    Papakostas GI, Petersen TJ, Burns AM, et al. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res 2006 Jun; 40: 370–3PubMedCrossRefGoogle Scholar
  109. 109.
    Fava M, Thase ME, DeBattista C. A multicenter, placebocontrolled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005 Jan; 66: 85–93PubMedCrossRefGoogle Scholar
  110. 110.
    Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 2008 Aug 1; 8: 29PubMedCrossRefGoogle Scholar
  111. 111.
    Lavretsky H, Kim MD, Kumar A, et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry 2003 Dec; 64: 1410–4PubMedCrossRefGoogle Scholar
  112. 112.
    Lavretsky H, Park S, Siddarth P, et al. Methylphenidateenhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006 Feb; 14: 181–5PubMedCrossRefGoogle Scholar
  113. 113.
    Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006 Feb; 11: 93–102PubMedGoogle Scholar
  114. 114.
    Holtzheimer 3rd PE, Meeks TW, Kelley ME, et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry 2008 Jun; 23: 625–31PubMedCrossRefGoogle Scholar
  115. 115.
    Pelton GH, Harper OL, Tabert MH, et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int J Geriatr Psychiatry 2008 Jul; 23: 670–6PubMedCrossRefGoogle Scholar
  116. 116.
    Fioravanti M, Buckley AE. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Interv Aging 2006; 1: 247–51PubMedCrossRefGoogle Scholar
  117. 117.
    Petkov VD, Stancheva SL, Tocuschieva L, et al. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen Pharmacol 1990; 21: 71–5PubMedCrossRefGoogle Scholar
  118. 118.
    Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 2007 Oct; 27: 498–502PubMedCrossRefGoogle Scholar
  119. 119.
    Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005 Apr 18; (2): CD000269Google Scholar
  120. 120.
    Spiers PA, Myers D, Hochanadel GS, et al. Citicoline improves verbal memory in aging. Arch Neurol 1996; 53: 441–8PubMedCrossRefGoogle Scholar
  121. 121.
    Salvadorini F, Galeone F, Nicotera M, et al. Clinical evaluation of CDP-choline (Nicholin): efficacy as antidepressant treatment. Curr Ther Res Clin Exp 1975 Sep; 18: 513–20PubMedGoogle Scholar
  122. 122.
    Goldberg JF, Harrow M. Subjective life satisfaction and objective functional outcome in bipolar and unipolar mood disorders: a longitudinal analysis. J Affect Disord 2005 Dec; 89: 79–89PubMedCrossRefGoogle Scholar
  123. 123.
    Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989 Mar; 27: S217–32PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Tracy L. Greer
    • 1
  • Benji T. Kurian
    • 1
  • Madhukar H. Trivedi
    • 1
  1. 1.Department of PsychiatryUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations